Krebs Biochemicals to merge with Ipca Laboratories
Krebs Biochemicals & Industries Ltd approved its amalgamation with Ipca Laboratories Ltd to secure fermentation-based API supply and drug intermediates. The appointed date is April 1, 2026, with an exchange ratio of 7 Ipca shares for every 200 Krebs shares.
*this image is generated using AI for illustrative purposes only.
Krebs Biochemicals & Industries Ltd's board has approved the amalgamation of the company with Ipca Laboratories Ltd to secure the supply of fermentation-based Active Pharmaceutical Ingredients (APIs) and drug intermediates. The merger, approved on June 26, 2026, aims to create operational synergies and consolidate the pharmaceutical manufacturing businesses of both entities. The appointed date for the scheme is April 1, 2026, and it will become effective upon receiving necessary regulatory consents.
The scheme of amalgamation is subject to approvals under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both entities are engaged in the manufacturing and marketing of pharmaceuticals. The transaction is classified as a related party transaction conducted at arm's length.
Financials and Rationale
The standalone audited total income of Ipca Laboratories Ltd for the financial year ended March 31, 2026, was Rs. 7431 Crores. In comparison, the audited total income of Krebs Biochemicals & Industries Ltd for the same period was Rs. 26 Crores, largely derived from conversion charges received from Ipca Laboratories Ltd.
The board outlined several reasons for the merger, including cost optimization, consolidation of business, and reduction of administrative and regulatory compliance burdens. Krebs Biochemicals & Industries Ltd possesses manufacturing capabilities for fermentation-based APIs that Ipca Laboratories Ltd currently lacks. The merger will enable Ipca Laboratories Ltd to research, develop, and commercialize new fermentation-based APIs. Additionally, the amalgamating company produces a fermentation-based API used in the largest selling formulation of the amalgamated company, and securing its supply is a key driver. Krebs Biochemicals & Industries Ltd has been incurring losses and is unable to spend on research and development, which the merger aims to address through the financial strength of Ipca Laboratories Ltd.
Share Exchange Ratio
The amalgamation involves a share swap without any cash consideration. Ipca Laboratories Ltd will issue and allot 7 fully paid-up equity shares of Re. 1/- each for every 200 fully paid-up equity shares of Rs. 10/- each held in Krebs Biochemicals & Industries Ltd. The record date for determining eligibility will be announced under the scheme.
Equity and preference shares held by Ipca Laboratories Ltd in Krebs Biochemicals & Industries Ltd will be cancelled and extinguished. No shares will be issued, and no consideration will be paid for this shareholding upon the effectiveness of the scheme.
| Particulars | Details |
|---|---|
| Transferor Company | Krebs Biochemicals & Industries Ltd |
| Transferee Company | Ipca Laboratories Ltd |
| Appointed Date | April 1, 2026 |
| Exchange Ratio | 7 shares of Ipca Labs for every 200 shares of Krebs Bio |
| Cash Consideration | None |
Historical Stock Returns for Krebs Biochemicals & Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.25% | -8.13% | -7.72% | -12.96% | -31.51% | -48.96% |
How will the integration of Krebs' fermentation capabilities impact Ipca Laboratories' R&D pipeline and time-to-market for new APIs?
What regulatory hurdles might the companies face given the significant disparity in their operational scales and financials?
How will Ipca Laboratories manage the financial burden of Krebs' accumulated losses post-merger?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
